- Trial phase
- Approved (FDA approved April 2009; marketed)
- Time to market
- Already approved and on the U.S. market (since April 2009)
- Why 3/10
- No hard, dated catalyst is scheduled for CREON in the next ~12 months: it has been FDA-approved since April 30, 2009 (the only catalyst on record locally), with no pending PDUFA, pivotal readout, or label-expansion decision in SecBot's FDA data, and it is a small, mature brand inside a large diversified portfolio, so impactScore is capped at 3.
Watch AbbVie's quarterly segment disclosures and the PERT competitive landscape (generic entry, pricing) for erosion signals, since those are the only ways this drug shows up in the stock's fundamentals.
Price Chart
Executive Summary
CREON (pancrelipase) is AbbVie's pancreatic enzyme replacement therapy (PERT), delayed-release capsules of porcine-derived digestive enzymes (lipase, protease, amylase), used to treat exocrine pancreatic insufficiency (EPI) in cystic fibrosis, chronic pancreatitis, pancreatectomy, and other conditions. It was FDA-approved in April 2009 and has been a commercial mainstay ever since; official AbbVie/HCP pages and AbbVie's own 10-K reference describe it as a pancreatic enzyme therapy for EPI. It is a mature, market-leading branded product with no pending regulatory binary, and it sits inside a large-cap pharma whose stock thesis is driven by other assets (analyst consensus is Buy-ish with mean target ~$270 vs ~$251 price). Third-party market reports estimate CREON at roughly $1.2–1.6B in 2024 U.S. revenues and flag generic/competitor erosion pressure.
How It Works
People with EPI don't make enough of the digestive enzymes the pancreas normally produces, so food isn't broken down and nutrients aren't absorbed. CREON replaces those enzymes: each capsule contains lipase, protease, and amylase extracted from pig pancreas glands, coated so the enzymes survive stomach acid and are released in the intestine (at pH ~5.5 or higher) where they help digest fat, protein, and carbohydrates. It is taken with every meal/snack, dosed in lipase units.
Trial Status
No ongoing pivotal trials for CREON/pancrelipase appear in SecBot's Phase 2/3 trial database or FDA catalyst feed, it is a fully commercialized product whose defining regulatory event (FDA approval) occurred in 2009. The only drug-specific catalyst on record locally is the 2009-04-30 fda_approval.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for CREON specifically in the next ~12 months; watch AbbVie quarterly earnings (next 8-K/earnings) for 'All Other'/segmented revenue trends that include CREON.
- Track generic or biosimilar-type PERT entrants and any supply/manufacturing disruptions that could affect CREON share.
- Any future FDA safety-labeling or shortage-list activity on pancreatic enzyme products would be the realistic near-term event to watch.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report